Working with its clients to ensure a successful outcome in terms of market access, Grove local consultants provide expert advice in three key areas:
Currently, the Kazakh market for pharmaceuticals is divided roughly equally into two: state procurement (via regional and city health departments and the remaining share bought directly by hospitals) and retail sales.
October 2018 sees the introduction of a phased introduction of a pricing policy (prescription pharmaceutical products in October 2018, followed by OTC drugs in 2023). This should benefit suppliers across the healthcare market. The National Center of Expertise (Ministry of Health) will be responsible for overseeing the associated product approval and certification process which will be based on a list drawn up by healthcare authorities. Both medicines and medical devices are to be included in the process.
The introduction of a clear pricing policy in Kazakhstan follows the previous updating of its reimbursement policy which is, in turn, based on Guaranteed Volume of Free Medical Aid (GVFMA). Policy changes have resulted in both an increase in the number of drugs on the reimbursement list and a fall in the cost to the patient for the drugs involved. Tender processes are clear. Tender details are announced by September with decisions made by November. The process is administered by the Ministry of Health.
The increasingly transparent local regulatory procedures still require careful navigation. Only with an understanding of local reimbursement policies, can new market entrants hope to get their own reimbursement strategies and subsequent reimbursement submissions right. With experienced local consultants, Grove can assist with: